--- title: "Pre-market hot trades in US stocks: MARIS - TECH pre-market down 9.39%; Profound Medical pre-market up 7.34%" type: "News" locale: "en" url: "https://longbridge.com/en/news/278389238.md" description: "MARIS - TECH pre-market down 9.39%; Profound Medical pre-market up 7.34%; Tianci pre-market up 186.37%; Relmada Therapeutics pre-market up 52.47%; Hims & Hers Health pre-market up 45.11%" datetime: "2026-03-09T12:12:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278389238.md) - [en](https://longbridge.com/en/news/278389238.md) - [zh-HK](https://longbridge.com/zh-HK/news/278389238.md) --- # Pre-market hot trades in US stocks: MARIS - TECH pre-market down 9.39%; Profound Medical pre-market up 7.34% **Pre-market Hot Trades in US Stocks** MARIS - TECH is down 9.39% in pre-market trading. Based on recent key news: 1. On March 6, Maris-Tech announced a securities purchase agreement with institutional investors to issue 1,605,136 shares of common stock at a price of $1.24 per share, expecting total proceeds of approximately $2 million. This news led to a pre-market drop of 21.5%. Source: Company announcement 2. On March 6, the company announced it received its first large production order from a new client in the defense sector, marking the transition of its Jupiter Drones video processing system from the evaluation phase to the operational supply phase. Despite this positive news, it failed to offset the stock price decline. Source: Company announcement 3. On March 6, the market expressed concerns about the company's competitiveness in the cybersecurity and telecommunications markets and the sustained demand for its products, increasing investor uncertainty. Source: Company announcement. The industry is highly competitive, and market uncertainty is rising. Profound Medical is up 7.34% in pre-market trading. Based on recent news, 1. On March 5, Profound Medical released its Q4 2026 financial report, showing an earnings per share of -$0.27, in line with expectations, but revenue increased by $1.8 million year-on-year. This indicates steady revenue growth for the company, driving the stock price up. 2. On March 5, the company announced the launch of the TULSA-AI volume reduction module and showcased real-world data from 500 TULSA procedures at the Busch Center. Additionally, the company announced the expansion of its direct sales team in North America and new distribution agreements, which boosted market confidence. 3. On March 5, Profound Medical's management clarified the path to profitability during the earnings call, emphasizing high-margin recurring revenue, operational scale expansion, and reimbursement progress, with an annual revenue target of $85 million. These strategic initiatives enhanced investor confidence in the company's future development. The medical device industry has performed strongly recently, with increasing market demand for innovative technologies. **Top Gainers in Pre-market US Stocks** Tianci is up 186.37% in pre-market trading, with no significant recent news. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Relmada Therapeutics is up 52.47% in pre-market trading. Based on recent key news: 1. On March 9, Relmada Therapeutics announced that its experimental bladder cancer drug NDV-01 helped most patients maintain a cancer-free status in a mid-term study. The company stated that 76% of high-risk patients were cancer-free after one year, and 95% showed complete response at some point. This news drove the stock price up 2. On March 9, Relmada Therapeutics conducted a private equity financing, expected to bring approximately $160 million in total revenue to the company. This move has enhanced market confidence in the company's financial condition, further driving up the stock price. 3. On March 9, Relmada Therapeutics emphasized the positive data of its NDV-01 drug, raising investor expectations for the company's future development and boosting the stock price. The biotechnology industry has been active recently, with significant capital inflows. Hims & Hers Health rose 45.11% in pre-market trading. Based on recent key news: 1. On March 9, Novo Nordisk plans to sell weight loss drugs on the Hims platform, ending the legal dispute between the two parties. This news drove Hims' stock price to surge 55% in pre-market trading. Source: Reuters 2. On March 9, analysts pointed out that if the agreement is confirmed, Hims may offer NovoCare pharmacy services, with a monthly fee of about $149, which has a lower profit margin than existing products. This agreement avoids long-term litigation and is favorable for Hims. Source: Bloomberg 3. On March 7, reports indicated that Novo Nordisk and Hims plan to announce a partnership, driving Hims' stock price up nearly 29% after hours. Source: Gelonghui The telemedicine market has huge potential, but legal risks should be noted ### Related Stocks - [MTEK.US](https://longbridge.com/en/quote/MTEK.US.md) - [PROF.US](https://longbridge.com/en/quote/PROF.US.md) ## Related News & Research - [Maris-Tech to Showcase Edge-Based Video Intelligence at Milipol TechX 2026 in Singapore | MTEK Stock News](https://longbridge.com/en/news/282550640.md) - [Is Coca‑Cola (KO) Offering Value After Recent Share Price Softness?](https://longbridge.com/en/news/282976703.md) - [BNY Declares Dividends | BK Stock News](https://longbridge.com/en/news/282982832.md) - [What is KeyCorp's Forecast for Tetra Tech FY2027 Earnings?](https://longbridge.com/en/news/282985711.md) - [Beyond SPY: Active ETFs Poised To Lead Next Phase Of $25 Trillion Industry Boom](https://longbridge.com/en/news/282571072.md)